跳至主要内容
临床试验/ISRCTN13331870
ISRCTN13331870进行中(未招募)1 期

An open controlled randomized clinical trial to study the clinical efficacy of the drug Eryxin produced by Namangan Pharm Plant

amangan Pharm Plant LTD0 个研究点目标入组 60 人开始时间: 2024年2月7日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Adults aged 18 years old and over
  • 2. Written informed consent to participate in the study
  • 3. With rheumatoid arthritis

排除标准

  • 1. Pregnancy
  • 2. Lactation
  • 3. Children aged under 18 years old
  • 4. Presence of hypersensitivity to the drug components
  • 5. Patient's participation in other clinical trials within the last 30 days
  • 6. Absence of informed written consent of the patient to participate in a clinical trial
  • 7. Hypersensitivity to the drug
  • 8. Genetically determined glucose-6-phosphate dehydrogenase deficiency (risk of hemolytic anemia)
  • 9. History of gastrointestinal bleeding or perforation associated with NSAID therapy
  • 10. Active peptic ulcer/bleeding or a history of recurrent peptic ulcer/bleeding (two or more cases of confirmed ulcer or bleeding)
  • 11. Hypersensitivity reactions (symptoms of asthma, rhinitis, angioedema, or urticaria) to other NSAIDs, including aspirin
  • 12. Severe liver dysfunction
  • 13. Severe impairment of renal function
  • 14. Chronic heart failure in decompensation stage

研究者

发起方
amangan Pharm Plant LTD

相似试验